Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126

Stress and the brain: from adaptation to disease

de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621

Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and β-Endorphin

Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965

Characterization of a 41-Residue Ovine Hypothalamic Peptide that Stimulates Secretion of Corticotropin and β-Endorphin

Vale, W., Spiess, J., RIVIER, C. L., & Rivier, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904

Stress and Depression

Hammen, C. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143938 · Cited by 2,979

Causal Relationship Between Stressful Life Events and the Onset of Major Depression

Kendler, K. S., Karkowski, L. M., & Prescott, C. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.837 · Cited by 2,566

The Corticosteroid Receptor Hypothesis of Depression

Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181

Animal models of neuropsychiatric disorders

Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023

The link between childhood trauma and depression: insights from HPA axis studies in humans

Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.03.008 · Cited by 1,704

Peptidergic neurones

Hökfelt, T. G. M., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,552

The Isolation of a New Hypotensive Peptide, Neurotensin, from Bovine Hypothalami

Carraway, R. E., & Leeman, S. E. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)43429-7 · Cited by 1,543

When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders

Raison, C. L., & Miller, A. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1554 · Cited by 1,197

Child sexual abuse and subsequent psychopathology: results from the National Comorbidity Survey

Molnar, B. E., Buka, S. L., & Kessler, R. C. (2001) · American Journal of Public Health · doi:10.2105/ajph.91.5.753 · Cited by 1,193

Dynamic DNA methylation programs persistent adverse effects of early-life stress

Murgatroyd, C., Patchev, A. V., Wu, Y., Micale, V., Bockmühl, Y., Fischer, D., Holsboer, F., Wotjak, C. T., Almeida, O. F. X., & Spengler, D. (2009) · Nature Neuroscience · doi:10.1038/nn.2436 · Cited by 1,162

Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors

Kramer, M. S., Cutler, N. R., Feighner, J. P., Shrivastava, R. K., Carman, J. S., Sramek, J. J., Reines, S. A., Liu, G. F., Snavely, D. B., Wyatt-Knowles, E. S., et al. (1998) · Science · doi:10.1126/science.281.5383.1640 · Cited by 1,071

Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin

Gillies, G. E., Linton, E. A., & Lowry, P. J. (1982) · Nature · doi:10.1038/299355a0 · Cited by 965

Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression

Chalmers, D., Lovenberg, T. W., & Souza, E. D. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-10-06340.1995 · Cited by 925

Clinical Characteristics of Women With a History of Childhood Abuse: Unhealed Wounds

McCauley, J. (1997) · JAMA · doi:10.1001/jama.1997.03540410040028 · Cited by 904

Antidepressants and Hypothalamic-Pituitary-Adrenocortical Regulation

HOLSBOER, F., & Barden, N. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-2-187 · Cited by 860

A Potent Nonpeptide Antagonist of the Substance P (NK 1 ) Receptor

Snider, R. M., Constantine, J. W., Lowe, J. A., III, Longo, K. P., Lebel, W. S., Woody, H. A., Drozda, S. E., Desai, M. C., Vinick, F. J., Spencer, R. W., et al. (1991) · Science · doi:10.1126/science.1703323 · Cited by 859

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705

Neuropsychopharmacology

Mathur, R. (2004) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/10243_6 · Cited by 669

The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety

Holsboer, F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)90056-5 · Cited by 654

Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders.

Coplan, J. D., Andrews, M. W., Rosenblum, L. A., Owens, M. J., Friedman, S., Gorman, J. M., & Nemeroff, C. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1619 · Cited by 649

Influence of Child Abuse on Adult Depression: Moderation by the Corticotropin-Releasing Hormone Receptor Gene

Bradley, R. G., Binder, E. B., Epstein, M. P., Tang, Y., Nair, H. P., Liu, W., Gillespie, C. F., Berg, T., Evces, M., Newport, D. J., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.26 · Cited by 643

Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age

Antoni, F. A. (1993) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1993.1004 · Cited by 636

Receptors and antagonists for substance P and related peptides.

Regoli, D. C., Boudon, A., & Fauchère, J. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06810-3 · Cited by 633

Regulation of pituitary ACTH secretion during chronic stress

Aguilera, G. (1994) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1994.1013 · Cited by 557

Structure and functional expression of the cloned rat neurotensin receptor

Tanaka, K., Masu, M., & Nakanishi, S. (1990) · Neuron · doi:10.1016/0896-6273(90)90137-5 · Cited by 537

The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum

de Vries, G. J., & Buijs, R. M. (1983) · Brain Research · doi:10.1016/0006-8993(83)90855-7 · Cited by 524

Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression

Reul, J. M. H. M. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00117-5 · Cited by 515

Neuropeptide S

Xu, Y.-L., Reinscheid, R. K., Huitrón‐Reséndiz, S., Clark, S. D., Wang, Z., Lin, S. H., Brücher, F., Zeng, J., Ly, N. K., Henriksen, S. J., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.005 · Cited by 514

Molecular cloning and expression of a rat Via arginine vasopressin receptor

Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477

Stress Hormone Regulation: Biological Role and Translation into Therapy

Holsboer, F., & Ising, M. (2010) · Annual Review of Psychology · doi:10.1146/annurev.psych.093008.100321 · Cited by 473

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders

Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471

Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress

Müller, M. B., Zimmermann, S., Sillaber, I., Hagemeyer, T. P., Deussing, J. M., Timpl, P., Kormann, M., Droste, S. K., Kühn, R., Reul, J. M. H. M., et al. (2003) · Nature Neuroscience · doi:10.1038/nn1123 · Cited by 458

Resilience to social stress coincides with functional DNA methylation of the Crf gene in adult mice

Elliott, E., Ezra-Nevo, G., Regev, L., Neufeld-Cohen, A., & Chen, A. (2010) · Nature Neuroscience · doi:10.1038/nn.2642 · Cited by 436

A potent and selective non-peptide antagonist of the neurokinin a (NK2) receptor

Emonds‐Alt, X., Vilain, P., Goulaouic, P., Proietto, V., Broeck, D. V., Advenier, C., Naline, E., Neliat, G., Fur, G. L., & Brelière, J. C. (1992) · Life Sciences · doi:10.1016/0024-3205(92)90352-p · Cited by 434

Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression

Purba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433

The 100-kDa Neurotensin Receptor Is gp95/Sortilin, A Non-G-Protein-coupled Receptor

Mazella, J., Zsürger, N., Navarro, V., Chabry, J., Kaghad, M., Caput, D., Ferrara, P., Vita, N., Gully, D., Maffrand, J., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26273 · Cited by 411

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

Holmes, A., Heilig, M. A., Rupniak, N. M. J., Steckler, T., & Griebel, G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.09.011 · Cited by 405

Hippocampal dysfunction and cognitive impairments provoked by chronic early-life stress involve excessive activation of CRH receptors

Ivy, A. S., Rex, C. S., Chen, Y., Dubé, C., Maras, P. M., Grigoriadis, D. E., Gall, C. M., Lynch, G., & Baram, T. Z. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1784-10.2010 · Cited by 402

Corticotropin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders

Souza, E. B. D. (1995) · Psychoneuroendocrinology · doi:10.1016/0306-4530(95)00011-9 · Cited by 397

Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates

Habib, K. E., Weld, K. P., Rice, K. C., Pushkas, J., Champoux, M., Listwak, S. J., WEBSTER, E. L., Atkinson, A. J., Schulkin, J. A., Contoreggi, C. S., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6079 · Cited by 396

Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression

Uhr, M., Tontsch, A., Namendorf, C., Ripke, S., Lucae, S., Ising, M., Dose, T., Ebinger, M., Rosenhagen, M. C., Kohli, M., et al. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.017 · Cited by 384

The galanin peptide family: Receptor pharmacology, pleiotropic biological actions, and implications in health and disease

LANG, R., Gundlach, A. L., & Kofler, B. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.05.009 · Cited by 382

Vasopressinergic regulation of the hypothalamic–pituitary–adrenal axis: implications for stress adaptation

Aguilera, G., & Rabadan-Diehl, C. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00196-8 · Cited by 375

Contribution of life events to causation of psychiatric illness

Paykel, E. S. (1978) · Psychological Medicine · doi:10.1017/s003329170001429x · Cited by 372

International Union of Pharmacology. XXXVI. Current Status of the Nomenclature for Receptors for Corticotropin-Releasing Factor and Their Ligands

Hauger, R. L., Grigoriadis, D. E., Dallman, M. F., Plotsky, P. M., Vale, W., & Dautzenberg, F. M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.3 · Cited by 365

Corticotropin Releasing Factor (CRF) Receptor Signaling in the Central Nervous System: New Molecular Targets

Hauger, R., Risbrough, V. B., Brauns, O., & Dautzenberg, F. M. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706777950684 · Cited by 344

Combined Dexamethasone/Corticotropin Releasing Hormone Test Predicts Treatment Response in Major Depression–A Potential Biomarker?

Ising, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, E. B., Kern, N., Künzel, H. E., Pfennig, A., Uhr, M., & Holsboer, F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.039 · Cited by 341

Extrapituitary expression of the rat V1b vasopressin receptor gene.

Lolait, S. J., O’Carroll, A., Mahan, L. C., Felder, C. C., Button, D. C., Young, W. S., Mezey, É., & Brownstein, M. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6783 · Cited by 337

Neuropeptides: opportunities for drug discovery

Hökfelt, T. G. M., Bartfai, T., & Bloom, F. E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00482-4 · Cited by 335

Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder

Meltzer, H. Y., Arvanitis, L. A., Bauer, D., Rein, W., & Meta-Trial Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.975 · Cited by 330

Neuropsychopharmacology

Stolerman, I. P. (2010) · Springer eBooks · doi:10.1007/978-3-540-68706-1_4410 · Cited by 322

Glutamatergic and Dopaminergic Neurons Mediate Anxiogenic and Anxiolytic Effects of CRHR1

Refojo, D., Schweizer, M., Kühne, C., Ehrenberg, S., Thoeringer, C. K., Vogl, A. M., Dedic, N., Schumacher, M., von Wolff, G., Avrabos, C., et al. (2011) · Science · doi:10.1126/science.1202107 · Cited by 321

Comparative Distribution of Vasopressin V1b and Oxytocin Receptor Messenger Ribonucleic Acids in Brain 1

Vaccari, C., Lolait, S. J., & Ostrowski, N. L. (1998) · Endocrinology · doi:10.1210/endo.139.12.6382 · Cited by 308

Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression

van Londen, L. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00054-7 · Cited by 306

The role of substance P in stress and anxiety responses

Ebner, K., & Singewald, N. (2006) · Amino Acids · doi:10.1007/s00726-006-0335-9 · Cited by 304

Mushroom bodies of the cockroach: Their participation in place memory

Mizunami, M., Weibrecht, J. M., & Strausfeld, N. J. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19981228)402:4 · Cited by 289

Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder

Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.013 · Cited by 286

Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus

Caffé, A. R., van Leeuwen, F. W., & Luiten, P. G. M. (1987) · Journal of Comparative Neurology · doi:10.1002/cne.902610206 · Cited by 286

Protective Effect of CRHR1 Gene Variants on the Development of Adult Depression Following Childhood Maltreatment: Replication and Extension

Polanczyk, G., Caspi, A., Williams, B., Price, T. S., Danese, A., Sugden, K., Uher, R., Poulton, R., & Moffitt, T. E. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.114 · Cited by 285

Prosocial effects of oxytocin and clinical evidence for its therapeutic potential

Striepens, N., Kendrick, K. M., Maier, W., & Hurlemann, R. (2011) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2011.07.001 · Cited by 283

Therapeutic potential of neuropeptide Y (NPY) receptor ligands

Brothers, S. P., & Wahlestedt, C. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000100 · Cited by 281

Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists

Rupniak, N. M. J., & Kramer, M. S. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01396-6 · Cited by 278

The combined dexamethasone/CRH test as a potential surrogate marker in depression

Ising, M., Kunzel, H. E., Binder, E. B., Nickel, T., Modell, S., & Holsboer, F. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.014 · Cited by 275

Behavioral Consequences of Intracerebral Vasopressin and Oxytocin: Focus on Learning and Memory **This paper is dedicated to our friend and scientific teacher Prof. Dr Armin Ermisch (1935–1995).

Engelmann, M., Wotjak, C. T., Neumann, I. D., Ludwig, M., & Landgraf, R. (1996) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(95)00059-3 · Cited by 269

Molecular cloning of a levocabastine‐sensitive neurotensin binding site

Chalon, P., Vita, N., Kaghad, M., Guillemot, M., Bonnin, J., Delpech, B., Fur, G. L., Ferrara, P., & Caput, D. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00397-3 · Cited by 267

Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity

Tyrka, A. R., Price, L. H., Gelernter, J., Schepker, C., Anderson, G. M., & Carpenter, L. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.05.012 · Cited by 264

Correlated memory defects and hippocampal dendritic spine loss after acute stress involve corticotropin-releasing hormone signaling

Chen, Y., Rex, C. S., Rice, C. J., Dubé, C. M., Gall, C. M., Lynch, G., & Baram, T. Z. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003825107 · Cited by 256

A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression

Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071199 · Cited by 254

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

Kramer, M. S., Winokur, A., Kelsey, J. E., Preskorn, S., Rothschild, A. J., Snavely, D. B., Ghosh, K., Ball, W. A., Reines, S. A., Munjack, D. J., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300260 · Cited by 254

Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress

Brunson, K. L., Eghbal-Ahmadi, M., Bender, R., Chen, Y., & Baram, T. Z. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151224898 · Cited by 236

SR 142801, The first potent non-peptide antagonist of the tachykinin NK3 receptor

Emonds‐Alt, X., Bichon, D., Ducoux, J.-P., Héaulme, M., Miloux, B., Poncelet, M., Proietto, V., Broeck, D. V., Vilain, P., Neliat, G., et al. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00413-m · Cited by 217

Estradiol increases the frequency of multiple synapse boutons in the hippocampal CA1 region of the adult female rat

Woolley, C. S., Wenzel, H. J., & Schwartzkroin, P. A. (1996) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19960909)373:1 · Cited by 213

Characterization of (2 S,4 R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist

Gal, C. S.-L., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrié, P., Nisato, D., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1122 · Cited by 211

Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents

Perrault, G., Griebel, G., & Sanger, D. J. (1998) · Psychopharmacology · doi:10.1007/s002130050645 · Cited by 210

Cerebral Blood Flow Changes After Treatment of Social Phobia with the Neurokinin-1 Antagonist GR205171, Citalopram, or Placebo

Furmark, T., Appel, L., Michelgård, Å., Wahlstedt, K., Åhs, F., Zancan, S., Jacobsson, E., Flyckt, K., Grohp, M., Bergström, M., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.029 · Cited by 208

Vasopressin-immunoreactive cell bodies in the bed nucleus of the stria terminalis of the rat

van Leeuwen, F., & Caffé, R. (1983) · Cell and Tissue Research · doi:10.1007/bf00211473 · Cited by 206

Clinical characteristics and treatment outcome in a representative sample of depressed inpatients – Findings from the Munich Antidepressant Response Signature (MARS) project

Hennings, J. M., Owashi, T., Binder, E. B., Horstmann, S., Menke, A., Kloiber, S. M., Dose, T., Wollweber, B., Spieler, D., Messer, T., et al. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.002 · Cited by 197

Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders.

Behan, D. P., Grigoriadis, D. E., Lovenberg, T. W., Chalmers, D. T., Heinrichs, S. C., Liaw, C. W., & Souza, E. B. D. (1996) · PubMed · Cited by 191

The Role of Corticotropin-Releasing Factor in the Pathogenesis of Major Depression

Nemeroff, C. B. (1988) · Pharmacopsychiatry · doi:10.1055/s-2007-1014652 · Cited by 188

Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment

Papiol, S., Arias, B., Gastó, C., Gutiérrez, B., Catalán, R., & Fañanás, L. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.02.017 · Cited by 188

Abnormalities in the Regulation of Vasopressin and Corticotropin Releasing Factor Secretion in Obsessive-Compulsive Disorder

Altemus, M. M. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820010009002 · Cited by 187

Cholecystokinin antagonists: Pharmacological and therapeutic potential

Herranz, R. (2003) · Medicinal Research Reviews · doi:10.1002/med.10042 · Cited by 184

Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: Association with major depression and antidepressant response in Mexican-Americans

Dong, C., Wong, M.-L., & Licinio, J. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.92 · Cited by 182

How can we realize the promise of personalized antidepressant medicines?

Holsboer, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2453 · Cited by 177

Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans

Licinio, J., O'Kirwan, F., Irizarry, K. J. L., Merriman, B., Thakur, S., Jepson, R., Lake, S. L., Tantisira, K. G., Weiss, S. T., & Wong, M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001587 · Cited by 173

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

Coric, V., Feldman, H., Oren, D. A., Shekhar, A., Pultz, J. A., Dockens, R. C., Wu, X., Gentile, K. A., Huang, S.-P., Emison, E., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20695 · Cited by 172

Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression

Zhou, J.-N., Riemersma, R. F., Unmehopa, U. A., Hoogendijk, W. J. G., van Heerikhuize, J. J., Hofman, M. A., & Swaab, D. F. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.7.655 · Cited by 172

Is There a Future for Neuropeptide Receptor Ligands in the Treatment of Anxiety Disorders?

Griebel, G. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00041-2 · Cited by 171

Forebrain CRF1Modulates Early-Life Stress-Programmed Cognitive Deficits

Wang, X., Rammes, G., Kraev, I., Wolf, M., Liebl, C., Scharf, S. H., Rice, C. J., Wurst, W., Holsboer, F., Deussing, J. M., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2259-11.2011 · Cited by 163

Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects

von Bardeleben, U., Holsboer, F., Stalla, G. K., & Müller, O. A. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90480-1 · Cited by 153

Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression

Liu, Z., Zhu, F., Wang, G., Xiao, Z., Wang, H., Tang, J., Wang, X., Qiu, D.-S., Liu, W., Cao, Z., et al. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.06.016 · Cited by 149

In Quest of Identifying Vulnerability Markers for Psychiatric Disorders by All-Night Polysomnography

Lauer, C. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950140063009 · Cited by 147

High-Affinity CRF1 Receptor Antagonist NBI-34041: Preclinical and Clinical Data Suggest Safety and Efficacy in Attenuating Elevated Stress Response

Ising, M., Zimmermann, U. S., Kunzel, H. E., Uhr, M., Foster, A. C., Learned, S. M., Holsboer, F., & Grigoriadis, D. E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301328 · Cited by 143

Localization of Vasopressin (V1a) Receptor Binding and mRNA in the Rhesus Monkey Brain

Young, Toloczko, & Insel (1999) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.1999.00332.x · Cited by 139

Evidence for a Role of the Supraopticohypophyseal System in Regulation of Adrenocorticotropic Secretion

McCann, S. M., & Brobeck, J. R. (1954) · Experimental Biology and Medicine · doi:10.3181/00379727-87-21368 · Cited by 139

The Effects of Deleting the Mouse Neurotensin Receptor NTR1 on Central and Peripheral Responses to Neurotensin

Pettibone, D. J., Hess, J. F., Hey, P. J., Jacobson, M. A., Leviten, M. W., Lis, E. V., Mallorga, P. J., Pascarella, D. M., Snyder, M. A., Williams, J. B., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.305 · Cited by 138

Neurotensin: Role in psychiatric and neurological diseases

Cáceda, R., Kinkead, B. L., & Nemeroff, C. B. (2006) · Peptides · doi:10.1016/j.peptides.2006.04.024 · Cited by 129

Localization of neuropeptide receptor mRNA in rat brain: Initial observations using probes for neurotensin and substance P receptors

Elde, R., Schalling, M., Ceccatelli, S., Nakanishi, S., & Hökfelt, T. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90187-e · Cited by 128

The involvement of the vasopressin system in stress-related disorders

Landgraf, R. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706776359664 · Cited by 127

Encyclopedia of Psychopharmacology

Baumann, P. (2010) · Springer eBooks · doi:10.1007/978-3-642-27772-6 · Cited by 127

NK3 receptor antagonists: the next generation of antipsychotics?

Spooren, W. P. J. M., Riemer, C., & Meltzer, H. Y. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1905 · Cited by 124

Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression

Held, K., Kunzel, H. E., Ising, M., Schmid, D. A., Zobel, A. W., Murck, H., Holsboer, F., & Steiger, A. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00076-1 · Cited by 123

The vasopressin Avpr1b receptor: Molecular and pharmacological studies

Roper, J. A., O'Carroll, A.-M., Young, W. S., & Lolait, S. (2010) · Stress · doi:10.3109/10253890.2010.512376 · Cited by 122

Tachykinin Receptors as Therapeutic Targets in Stress-Related Disorders

Ebner, K., Sartori, S. B., & Singewald, N. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168074 · Cited by 121

The Gerbil Elevated Plus-maze II Anxiolytic-like Effects of Selective Neurokinin NK1 Receptor Antagonists

Varty, G. B. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00313-5 · Cited by 120

Identification and characterization of a 3',5'-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter

Spengler, D., Rupprecht, R., Phi‐van, L., & Holsboer, F. (1992) · Molecular Endocrinology · doi:10.1210/mend.6.11.1480179 · Cited by 120

Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder

Keck, M. E., Kern, N., Erhardt, A., Unschuld, P. G., Ising, M., Salyakina, D., Müller, M. B., Knorr, C. C., Lieb, R., Hohoff, C., et al. (2008) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30750 · Cited by 117

Association of Polymorphisms in Genes Regulating the Corticotropin-Releasing Factor System With Antidepressant Treatment Response

Binder, E. B., Owens, M. J., Liu, W., Deveau, T. C., Rush, A. J., Trivedi, M. H., D, M. F. M., Bradley, B., Ressler, K. J., & Nemeroff, C. B. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.18 · Cited by 113

Childhood maltreatment, the corticotropin‐releasing hormone receptor gene and adult depression in the general population

Grabe, H., Schwahn, C., Appel, K., Mahler, J., Schulz, A., Spitzer, C., Fenske, K., Barnow, S., Lucht, M., Freyberger, H., et al. (2010) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31131 · Cited by 113

Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor

Gehlert, D. R., Shekhar, A., Morin, S. M., Hipskind, P. A., Zink, C., Gackenheimer, S. L., Shaw, J., Fitz, S. D., & Sajdyk, T. J. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.12.030 · Cited by 112

Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415

Stemmelin, J., Lukovic, L., Salome, N., & Griebel, G. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300562 · Cited by 112

Substance P Receptor Antagonists in Psychiatry

Herpfer, I., & Lieb, K. (2005) · CNS Drugs · doi:10.2165/00023210-200519040-00001 · Cited by 111

Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep

Kimura, M., Müller-Preuss, P., Lu, A., Wiesner, E., Flachskamm, C., Wurst, W., Holsboer, F., & Deussing, J. M. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.46 · Cited by 111

Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig

Marco, N., Thirion, A., Mons, G., Bougault, I., Fur, G. L., Soubrié, P., & Steinberg, R. (1998) · Neuropeptides · doi:10.1016/s0143-4179(98)90075-0 · Cited by 104

Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas

Refojo, D., Echenique, C., Müller, M. B., Reul, J. M. H. M., Deussing, J. M., Wurst, W., Sillaber, I., Páez-Pereda, M., Holsboer, F., & ARZT, E. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502070102 · Cited by 103

Quality of Life of Adolescents With Perceived Disabilities

Edwards, T. C. (2003) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsg011 · Cited by 103

Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety

Keck, M. E. (2006) · Amino Acids · doi:10.1007/s00726-006-0333-y · Cited by 95

Transient Early-Life Forebrain Corticotropin-Releasing Hormone Elevation Causes Long-Lasting Anxiogenic and Despair-Like Changes in Mice

Kolber, B. J., Boyle, M. P., Wieczorek, L., Kelley, C. L., Onwuzurike, C., Nettles, S. A., Vogt, S. K., & Muglia, L. J. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4470-09.2010 · Cited by 95

Selective Blockade of Neurokinin-2 Receptors Produces Antidepressant-Like Effects Associated with Reduced Corticotropin-Releasing Factor Function

Steinberg, R., Alonso, R., Griebel, G., Bert, L., Jung, M., Oury-Donat, F., Poncelet, M., Gueudet, C., Desvignes, C., Fur, G. L., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29250-8 · Cited by 93

The Gerbil Elevated Plus-Maze I Behavioral Characterization and Pharmacological Validation

Varty, G. B. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00312-3 · Cited by 87

Intranasally Administered Neuropeptide S (NPS) Exerts Anxiolytic Effects Following Internalization Into NPS Receptor-Expressing Neurons

Ionescu, I. A., Dine, J., Yen, Y.-C., Buell, D. R., Herrmann, L., Holsboer, F., Eder, M., Landgraf, R., & Schmidt, U. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.317 · Cited by 87

Highly potent neurotensin analog that causes hypothermia and antinociception

Tyler-McMahon, B. M., Stewart, J. A., Fariñas, F., McCormick, D., & Richelson, E. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00877-8 · Cited by 86

Non-Peptide Vasopressin V1b Receptor Antagonists as Potential Drugs for the Treatment of Stress-Related Disorders

Griebel, G., Stemmelin, J., Gal, C. S., & Soubrié, P. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053764797 · Cited by 86

Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody

Fassio, A., Evans, G., Grisshammer, R., Bolam, J. P., Mimmack, M. L., & Emson, P. C. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00060-5 · Cited by 86

Species differences in tachykinin receptor distribution: Further evidence that the substance P (NK1) receptor predominates in human brain

Rigby, M., O’Donnell, R., & Rupniak, N. M. J. (2005) · The Journal of Comparative Neurology · doi:10.1002/cne.20664 · Cited by 78

Melanin-Concentrating Hormone MCH1 Receptor Antagonists

Shimazaki, T., Yoshimizu, T., & Chaki, S. (2006) · CNS Drugs · doi:10.2165/00023210-200620100-00002 · Cited by 76

Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs

Gobbi, G., & Blier, P. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.032 · Cited by 72

A 25 year adventure in the field of tachykinins

Beaujouan, J., Torrens, Y., Saffroy, M., Kemel, M. L., & Glowinski, J. (2004) · Peptides · doi:10.1016/j.peptides.2004.02.011 · Cited by 72

Trillion-dollar brain drain

Smith, K. (2011) · Nature · doi:10.1038/478015a · Cited by 71

Desmopressin Normalizes the Blunted Adrenocorticotropin Response to Corticotropin-Releasing Hormone in Melancholic Depression: Evidence of Enhanced Vasopressinergic Responsivity

Dinan, T. G., Lavelle, E., Scott, L. V., Newell-Price, J. D. C., Medbak, S., & Grossman, A. B. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5723 · Cited by 70

In vitro binding and CNS effects of novel neurotensin agonists that cross the blood–brain barrier

Tyler, B. M., Douglas, C. L., Fauq, A. H., Pang, Y., Stewart, J. A., Cusack, B. M., McCormick, D., & Richelson, E. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00011-8 · Cited by 70

Cerebrospinal Fluid Vasopressin—Changes in Depression

Gjerris, A., Vendsborg, P. B., HAMMER, M., Christensen, N. J., & Rafaelsen, O. J. (1985) · The British Journal of Psychiatry · doi:10.1192/bjp.147.6.696 · Cited by 69

Binding of the Non-Peptide Vasopressin V1a Receptor Antagonist SR-49059 in the Rat Brain: An in vitro and in vivo Autoradiographic Study

Tribollet, E., Raufaste, D., Maffrand, J., & Gal, C. S. (1999) · Neuroendocrinology · doi:10.1159/000054409 · Cited by 66

Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder

Ratti, E., Bellew, K. M., Bettica, P. U., Bryson, H., Zamuner, S., Archer, G. E., Squassante, L., Bye, A., Trist, D. G., Krishnan, K. R. R., et al. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823608ca · Cited by 64

Therapeutic Plasma Concentrations of Antidepressants and Antipsychotics: Lessons from PET Imaging

Gründer, G., Hiemke, C., Paulzen, M., Veselinovic, T., & Vernaleken, I. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286282 · Cited by 62

Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models

Louis, C., Stemmelin, J., Boulay, D., Bergis, O. E., Cohen, C., & Griebel, G. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.10.020 · Cited by 59

Effects of SR48968, a selective non-peptide NK 2 receptor antagonist on emotional processes in rodents

Griebel, G., Perrault, G., & Soubrié, P. (2001) · Psychopharmacology · doi:10.1007/s002130100830 · Cited by 57

Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder

Tauscher, J. T., Kielbasa, W., Iyengar, S., Vandenhende, F., Peng, X., Mozley, D. P., Gehlert, D. R., & Marek, G. J. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.10.005 · Cited by 56

A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial

Mathew, S. J., Vythilingam, M., Murrough, J. W., Zarate, C. A., Feder, A., Luckenbaugh, D. A., Kinkead, B. L., Parides, M. K., Trist, D. G., Bani, M., et al. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.11.012 · Cited by 55

Neuropeptides in Psychiatric Diseases: An Overview with a Particular Focus on Depression and Anxiety Disorders

Surget, A., Leman, S., Griebel, G., Belzung, C., & Yalçın, İ. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706776359682 · Cited by 52

Neurotensin Agonists

Boules, M., Shaw, A. M., Fredrickson, P. A., & Richelson, E. (2007) · CNS Drugs · doi:10.2165/00023210-200721010-00002 · Cited by 49

The Orphanin FQ/Nociceptin (OFQ/N) System

Civelli, O. (2008) · Springer eBooks · doi:10.1007/400_2007_057 · Cited by 49

Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol

Liem-Moolenaar, M., Gray, F., de Visser, S. J., Franson, K. L., Schoemaker, R. C., Schmitt, J. A. J., Cohen, A., & van Gerven, J. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094524 · Cited by 42

Novel Treatments of Schizophrenia: Targeting the Neurotensin System

Kinkead, B. L., & Nemeroff, C. B. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706776359655 · Cited by 40

Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 – 2010)

Malherbe, P., Ballard, T. M., & Ratni, H. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.568482 · Cited by 38

Randomized, Double-Blind Study of SR142801 (Osanetant). A Novel Neurokinin-3 (NK3) Receptor Antagonist in Panic Disorder with Pre- and Posttreatment Cholecystokinin Tetrapeptide (CCK-4) Challenges

Kronenberg, G., Berger, P., Tauber, R., Bandelow, B., Henkel, V., & Heuser, I. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-837768 · Cited by 34

Pharmacokinetics of Novel Hexapeptides with Neurotensin Activity in Rats.

MACHIDA, R., Tokumura, T., TSUCHIYA, Y., SASAKI, A., & Kouichi, A. B. E. (1993) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.16.43 · Cited by 33

NK 1 receptor antagonism and emotional processing in healthy volunteers

Chandra, P., Hafizi, S., Massey-Chase, R., Goodwin, G., Cowen, P., & Harmer, C. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109103101 · Cited by 30

Dose Response of Arginine Vasopressin to the CCK-B Agonist Pentagastrin

Abelson, J. L. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00182-2 · Cited by 30

Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?

Griebel, G., & Beeské, S. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.007 · Cited by 29

Therapeutic Utility of NK3 Receptor Antagonists for the Treatment of Schizophrenia

Dawson, L. A., & Smith, P. W. (2009) · Current Pharmaceutical Design · doi:10.2174/138161210790170067 · Cited by 29

Is bigger better for depression trials?

Liu, K. S., Snavely, D. B., Ball, W. A., Lines, C. R., Reines, S. A., & Potter, W. Z. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.07.003 · Cited by 28

The Melanin-Concentrating Hormone (MCH) System Modulates Behaviors Associated with Psychiatric Disorders

Chung, S., Verheij, M. M. M., Hesseling, P., van Vugt, R. W. M., Buell, M. R., Belluzzi, J. D., Geyer, M. A., Martens, G. J. M., & Civelli, O. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019286 · Cited by 27

NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers

McCabe, C., Cowen, P. J., & Harmer, C. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990150 · Cited by 27

Characterization of a novel and selective V1B receptor antagonist

Craighead, M. W., Milne, R. J., Campbell-Wan, L., WATSON, L., Presland, J. P., THOMSON, F. J., Marston, H. M., & MacSweeney, C. P. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00440-8 · Cited by 25

PET Imaging of CRF1 with [11C]R121920 and [11C]DMP696: is the target of sufficient density?

Sullivan, G. M., Parsey, R. V., Kumar, J. S. D., Arango, V., Kassir, S. A., Huang, Y.-Y., Simpson, N. R., Heertum, R. L. V., & Mann, J. J. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.01.012 · Cited by 25

Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties

Boules, M., McMahon, B. M., Warrington, L. E., Stewart, J. A., Jackson, J. G., Fauq, A. H., McCormick, D., & Richelson, E. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02981-x · Cited by 25

Restriction of HIV-1 Replication in Monocytes Is Abolished by Vpx of SIVsmmPBj

Schüle, S., Kloke, B., Kaiser, J. K., Heidmeier, S., Panitz, S., Wolfrum, N., Cichutek, K., & Schweizer, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007098 · Cited by 23

Discontinued psychiatric drugs in 2008

Kirchhoff, V., Nguyen, H. T., Soczynska, J. K., Woldeyohannes, H. O., & McIntyre, R. S. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903184591 · Cited by 22

Developing Small Molecule Nonpeptidergic Drugs for the Treatment of Anxiety Disorders: Is the Challenge Still Ahead?

Steckler, T. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_14 · Cited by 21

Stability of a novel hexapeptide, (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu-OEt, with neurotensin activity, in aqueous solution and in the solid state.

Tokumura, T., TANAKA, T., SASAKI, A., TSUCHIYA, Y., Kouichi, A. B. E., & Machida, R. (1990) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.38.3094 · Cited by 21

Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression

Overstreet, D. H., Naimoli, V., & Griebel, G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.05.006 · Cited by 19

Novel NK(3) receptor antagonists for the treatment of schizophrenia and other CNS indications.

Simonsen, K. B., Juhl, K., Steiniger‐Brach, B., & Nielsen, S. M. (2010) · PubMed · Cited by 19

Short-term NK1 receptor antagonism and emotional processing in healthy volunteers

Pringle, A., McTavish, S. F., Williams, C., Smith, R., Cowen, P. J., & Harmer, C. J. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2133-z · Cited by 18

Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment

Paslakis, G., Luppa, P. B., Gilles, M., Kopf, D., Weber-Hamann, B., Lederbogen, F., & Deuschle, M. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.11.015 · Cited by 17

Conditional CRH overexpressing mice: an animal model for stress-elicited pathologies and treatments that target the central CRH system

Lu, A., Steiner, M. A., Whittle, N., Vogl, A. M., Walser, S. M., Ableitner, M., Refojo, D., Ekker, M., Rubenstein, J. L. R., Stalla, G. K., et al. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.107 · Cited by 17

Talnetant GlaxoSmithKline.

Evangelista, S. (2005) · PubMed · Cited by 15

Effects of neurotensin receptor antagonists on the firing rate of rat ventral pallidum neurons

Michaud, J.-C., Gueudet, C., & Soubrié, P. (2000) · Neuroreport · doi:10.1097/00001756-200005150-00017 · Cited by 13

Identification of a new series of non-peptidic NK3 receptor antagonists

Juhl, K., Hansen, T., Kehler, J., Khanzhin, N. A., Nørgaard, M. B., Ruhland, T., Larsen, D. B., Jensen, K. G., Steiniger‐Brach, B., Nielsen, S. M., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.135 · Cited by 7

[Neurotensin, a multi-action peptide hormone].

St-Pierre, S. A., Quirion, R., Regoli, D. C., Gervais, A., Lavigne, F., Poirier, A., JOLICOEUR, F. B., Barbeau, A., & Rioux, F. (1980) · PubMed · Cited by 4

Überlegungen zur Wirksamkeit von Psychopharmaka

Leucht, S., Heres, S., & Davis, J. M. (2011) · Der Nervenarzt · doi:10.1007/s00115-011-3349-9 · Cited by 3

Tachykinins

Turiault, M., Cohen, C., & Griebel, G. (2010) · Springer eBooks · doi:10.1007/978-3-540-68706-1_210 · Cited by 3

Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors

Neumann, I. D., & Landgraf, R. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.08.004 · Cited by 954

Structure of the agonist-bound neurotensin receptor

White, J. F., Noinaj, N., Shibata, Y., Love, J. D., Kloss, B., Xu, F., Gvozdenovic‐Jeremic, J., Shah, P., Shiloach, J., Tate, C. G., et al. (2012) · Nature · doi:10.1038/nature11558 · Cited by 527

Neurobiology of opioid addiction: Opponent process, hyperkatifeia, and negative reinforcement

Koob, G. F. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.023 · Cited by 477

HPA Axis in the Pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation

Mikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450

Detecting Activated Cell Populations Using Single-Cell RNA-Seq

Wu, Y. E., Pan, L., Zuo, Y., Li, X., & Hong, W. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.026 · Cited by 438

The Role of Peptides in Treatment of Psychiatric Disorders

Holsboer, F. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6020-6_2 · Cited by 35

Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins

Griebel, G. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150605105859 · Cited by 7

Clinical trials of neuropeptides in psychiatric disorders.

(1982) · PubMed

Neuropeptides in Psychiatry

Suchak, V., Sathyanath, S., & Kakunje, A. (2022) · Archives of Medicine and Health Sciences · doi:10.4103/amhs.amhs_91_22 · Cited by 12

Neuropeptide Systems and Schizophrenia

LaCrosse, A., & Olive, M. F. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312050010 · Cited by 39